Bicara Therapeutics (NASDAQ:BCAX) Receives New Coverage from Analysts at Morgan Stanley

Morgan Stanley started coverage on shares of Bicara Therapeutics (NASDAQ:BCAX) in a research note issued to investors on Tuesday, MarketBeat Ratings reports. The brokerage issued an overweight rating and a $35.00 target price on the stock.

A number of other brokerages also recently weighed in on BCAX. TD Cowen began coverage on shares of Bicara Therapeutics in a report on Tuesday. They issued a buy rating for the company. Stifel Nicolaus started coverage on shares of Bicara Therapeutics in a research report on Tuesday. They issued a buy rating and a $47.00 target price for the company.

Bicara Therapeutics Stock Performance

Bicara Therapeutics stock opened at $19.00 on Tuesday. Bicara Therapeutics has a 12-month low of $18.58 and a 12-month high of $27.94.

Insider Transactions at Bicara Therapeutics

In related news, Director Ra Capital Management, L.P. bought 1,833,000 shares of Bicara Therapeutics stock in a transaction dated Monday, September 16th. The shares were bought at an average cost of $18.00 per share, for a total transaction of $32,994,000.00. Following the completion of the transaction, the director now owns 4,303,418 shares of the company’s stock, valued at approximately $77,461,524. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, Director Ra Capital Management, L.P. bought 1,833,000 shares of the company’s stock in a transaction dated Monday, September 16th. The stock was bought at an average price of $18.00 per share, for a total transaction of $32,994,000.00. Following the completion of the transaction, the director now directly owns 4,303,418 shares in the company, valued at $77,461,524. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder James E. Flynn bought 70,000 shares of Bicara Therapeutics stock in a transaction dated Tuesday, September 17th. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $1,260,000.00. Following the purchase, the insider now directly owns 897,587 shares in the company, valued at approximately $16,156,566. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.